231 related articles for article (PubMed ID: 22031238)
1. Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs.
Deyle DR; Khan IF; Ren G; Wang PR; Kho J; Schwarze U; Russell DW
Mol Ther; 2012 Jan; 20(1):204-13. PubMed ID: 22031238
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Modelling of Osteogenesis Imperfecta with Patient-Derived Induced Mesenchymal Stem Cells.
Claeys L; Zhytnik L; Ventura L; Wisse LE; Eekhoff EMW; Pals G; Bravenboer N; Heine VM; Micha D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542391
[TBL] [Abstract][Full Text] [Related]
3. Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta.
Chamberlain JR; Deyle DR; Schwarze U; Wang P; Hirata RK; Li Y; Byers PH; Russell DW
Mol Ther; 2008 Jan; 16(1):187-93. PubMed ID: 17955022
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of osteogenesis in iPSC-derived mesenchymal stem cells from osteogenesis imperfecta patients by endoplasmic reticulum stress inhibitor.
Duangchan T; Tawonsawatruk T; Angsanuntsukh C; Trachoo O; Hongeng S; Kitiyanant N; Supokawej A
Life Sci; 2021 Aug; 278():119628. PubMed ID: 34015290
[TBL] [Abstract][Full Text] [Related]
5. Galunisertib downregulates mutant type I collagen expression and promotes MSCs osteogenesis in pediatric osteogenesis imperfecta.
Infante A; Alcorta-Sevillano N; Macías I; Cabodevilla L; Medhat D; Lafaver B; Crawford TK; Phillips CL; Bueno AM; Sagastizabal B; Arroyo M; Campino A; Gerovska D; Araúzo-Bravo M; Gener B; Rodríguez CI
Biomed Pharmacother; 2024 Jun; 175():116725. PubMed ID: 38744219
[TBL] [Abstract][Full Text] [Related]
6. Gene targeting in stem cells from individuals with osteogenesis imperfecta.
Chamberlain JR; Schwarze U; Wang PR; Hirata RK; Hankenson KD; Pace JM; Underwood RA; Song KM; Sussman M; Byers PH; Russell DW
Science; 2004 Feb; 303(5661):1198-201. PubMed ID: 14976317
[TBL] [Abstract][Full Text] [Related]
7. Genotypic Characterization of a Chinese Family with Osteogenesis Imperfecta and Generation of Disease-Specific Induced Pluripotent Stem Cells.
Li D; Ou M; Dai G; Zhu P; Luo Q; Chen J; Shah Z; Samokhvalov IM; Yin L; Sun G; Tang D; Dai Y
Front Biosci (Landmark Ed); 2023 Dec; 28(12):336. PubMed ID: 38179771
[TBL] [Abstract][Full Text] [Related]
8. Potential of gene therapy for treating osteogenesis imperfecta.
Niyibizi C; Smith P; Mi Z; Robbins P; Evans C
Clin Orthop Relat Res; 2000 Oct; (379 Suppl):S126-33. PubMed ID: 11039761
[TBL] [Abstract][Full Text] [Related]
9. Validation in mesenchymal progenitor cells of a mutation-independent ex vivo approach to gene therapy for osteogenesis imperfecta.
Millington-Ward S; Allers C; Tuohy G; Conget P; Allen D; McMahon HP; Kenna PF; Humphries P; Farrar GJ
Hum Mol Genet; 2002 Sep; 11(19):2201-6. PubMed ID: 12217948
[TBL] [Abstract][Full Text] [Related]
10. The synergistic effect of NELL1 and adipose-derived stem cells on promoting bone formation in osteogenesis imperfecta treatment.
Liu Y; Ju M; Wang Z; Li J; Shao C; Fu T; Jing Y; Zhao Y; Lv Z; Li G
Biomed Pharmacother; 2020 Aug; 128():110235. PubMed ID: 32454289
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy approaches for osteogenesis imperfecta.
Niyibizi C; Wang S; Mi Z; Robbins PD
Gene Ther; 2004 Feb; 11(4):408-16. PubMed ID: 14724682
[TBL] [Abstract][Full Text] [Related]
12. Transfer of proalpha2(I) cDNA into cells of a murine model of human Osteogenesis Imperfecta restores synthesis of type I collagen comprised of alpha1(I) and alpha2(I) heterotrimers in vitro and in vivo.
Niyibizi C; Smith P; Mi Z; Phillips CL; Robbins P
J Cell Biochem; 2001 Jun 26-Jul 25; 83(1):84-91. PubMed ID: 11500956
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic antibody directed osteogenic differentiation of induced pluripotent stem cell derived MSCs.
Wu Q; Yang B; Cao C; Hu K; Wang P; Man Y
Acta Biomater; 2018 Jul; 74():222-235. PubMed ID: 29778895
[TBL] [Abstract][Full Text] [Related]
14. Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms.
Otsuru S; Gordon PL; Shimono K; Jethva R; Marino R; Phillips CL; Hofmann TJ; Veronesi E; Dominici M; Iwamoto M; Horwitz EM
Blood; 2012 Aug; 120(9):1933-41. PubMed ID: 22829629
[TBL] [Abstract][Full Text] [Related]
15. Targeting gene therapy for osteogenesis imperfecta.
Prockop DJ
N Engl J Med; 2004 May; 350(22):2302-4. PubMed ID: 15163783
[No Abstract] [Full Text] [Related]
16. Progenitors systemically transplanted into neonatal mice localize to areas of active bone formation in vivo: implications of cell therapy for skeletal diseases.
Wang X; Li F; Niyibizi C
Stem Cells; 2006 Aug; 24(8):1869-78. PubMed ID: 16675597
[TBL] [Abstract][Full Text] [Related]
17. Conditioned Medium Enhances Osteogenic Differentiation of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells.
Zhong S; He X; Li Y; Lou X
Tissue Eng Regen Med; 2019 Apr; 16(2):141-150. PubMed ID: 30989041
[TBL] [Abstract][Full Text] [Related]
18. Osteoblastic differentiation of bone marrow mesenchymal stromal cells in Bruck Syndrome.
Kaneto CM; Lima PS; Zanette DL; Oliveira TY; de Assis Pereira F; Lorenzi JC; Dos Santos JL; Prata KL; Neto JM; de Paula FJ; Silva WA
BMC Med Genet; 2016 May; 17(1):38. PubMed ID: 27146342
[TBL] [Abstract][Full Text] [Related]
19. Allele-specific gene silencing in osteogenesis imperfecta.
Ljunggren Ö; Lindahl K; Rubin CJ; Kindmark A
Endocr Dev; 2011; 21():85-90. PubMed ID: 21865757
[TBL] [Abstract][Full Text] [Related]
20. Human iPSC-derived MSCs (iMSCs) from aged individuals acquire a rejuvenation signature.
Spitzhorn LS; Megges M; Wruck W; Rahman MS; Otte J; Degistirici Ö; Meisel R; Sorg RV; Oreffo ROC; Adjaye J
Stem Cell Res Ther; 2019 Mar; 10(1):100. PubMed ID: 30885246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
